Sivik Global Healthcare LLC Decreases Stock Holdings in Abbott Laboratories $ABT

Key Points

• Sivik Global Healthcare LLC reduced its holdings in Abbott Laboratories by 12.9%, now owning 39,200 shares valued at approximately $5.3 million.
• Several hedge funds, including Brighton Jones LLC and GAMMA Investing LLC, have increased their stakes in Abbott Laboratories, indicating continued institutional interest in the stock.
• Analyst ratings for Abbott Laboratories vary, with price targets ranging from $141 to $157, and an average rating of "Moderate Buy".

Sivik Global Healthcare LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 12.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,200 shares of the healthcare product maker's stock after selling 5,800 shares during the period. Abbott Laboratories makes up approximately 1.5% of Sivik Global Healthcare LLC's holdings, making the stock its 19th biggest holding. Sivik Global Healthcare LLC's holdings in Abbott Laboratories were worth $5,332,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ABT. Brighton Jones LLC raised its holdings in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after acquiring an additional 4,755 shares in the last quarter. GAMMA Investing LLC raised its holdings in Abbott Laboratories by 17.0% during the 1st quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker's stock valued at $5,103,000 after buying an additional 5,590 shares during the period. West Branch Capital LLC raised its holdings in Abbott Laboratories by 13.3% during the 1st quarter. West Branch Capital LLC now owns 17,677 shares of the healthcare product maker's stock valued at $2,345,000 after buying an additional 2,080 shares during the period. CVA Family Office LLC raised its holdings in Abbott Laboratories by 2.5% during the 1st quarter. CVA Family Office LLC now owns 7,555 shares of the healthcare product maker's stock valued at $1,002,000 after buying an additional 183 shares during the period. Finally, Goldstone Financial Group LLC raised its holdings in Abbott Laboratories by 39.8% during the 1st quarter. Goldstone Financial Group LLC now owns 13,901 shares of the healthcare product maker's stock valued at $1,844,000 after buying an additional 3,954 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ABT shares. Raymond James Financial decreased their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. Mizuho increased their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Morgan Stanley increased their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a research note on Monday, June 16th. Finally, The Goldman Sachs Group increased their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a "buy" rating in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $146.17.

Abbott Laboratories Stock Performance

ABT stock opened at $132.30 on Friday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The business's fifty day simple moving average is $132.54 and its two-hundred day simple moving average is $131.60. The firm has a market cap of $230.26 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.51 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the prior year, the firm earned $1.14 earnings per share. The firm's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's dividend payout ratio is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.